MTOR and leukemia: Initial studies using (non-CRLF2-rearranged) murine B-ALL models identified activation of PI3K/mTOR signaling in these leukemias, which was modulated by IL-7 and TSLP and could be abrogated in vitro and in vivo by sirolimus treatment (24, 25).